{"id":"NCT00627016","sponsor":"Takeda","briefTitle":"A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn","officialTitle":"A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-02-29","resultsPosted":"2010-05-06","lastUpdate":"2011-04-28"},"enrollment":305,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"Dexlansoprazole","otherNames":["TAK-390","T-168390","TAK-390MR","Kapidex","Dexilant"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dexlansoprazole 30 mg QD","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.","primaryOutcome":{"measure":"Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.","timeFrame":"4 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":35.7,"sd":30},{"arm":"Dexlansoprazole 30 mg QD","deltaMin":73.1,"sd":35}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":20},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["21224838"],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=9efb34b3-fb69-4190-a2be-a90b8cb94e25&filetypecode=DEXILANTPI"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["Upper Respiratory Tract Infections"]}}